Evaluation model and efficacy of multimodal ultrasound imaging technology to predict the efficacy of neoadjuvant chemotherapy in breast cancer

Objective: To investigate the value of multimodal ultrasound imaging indicators in evaluating the efficacy of neoadjuvant chemotherapy for breast cancer, and to establish a multivariate Logistic regression model for evaluating neoadjuvant chemotherapy for breast cancer. Methods: A retrospective analysis of 38 breast cancer patients who underwent surgery after neoadjuvant chemotherapy was divided into pathologically ineffective (NMHR) and pathologically effective (MHR) according to Miller & Payne grading method. The image characteristics of conventional ultrasound, elastography, and contrast-enhanced ultrasound parameters were compared between the two groups. Univariate and multivariate Logistic analyses were used to analyze factors affecting the efficacy of neoadjuvant chemotherapy. The receiver operating curve (ROC) of each factor was drawn, and the area under the ROC curve and evaluation indicators such as sensitivity and specificity were calculated. Results: After neoadjuvant chemotherapy in the effective group (MHR), the tumor's longest diameter reduction rate (ΔD), morphology, margin, posterior echo attenuation, calcification, resistance index (RI), peak systole velocity (peak systole velocity, PSV), strain ratio (SR), elasticity score, peak intensity (PI) and time to peak (TTP) were the factors affecting the efficacy of neoadjuvant chemotherapy (P<0.05). The factor Logistic regression model showed that the longest tumor diameter reduction rate, PSV, SR, PI, TTP were reliable factors for the efficacy of neoadjuvant chemotherapy in breast cancer. The area under the ROC curve of the multivariate logistic regression model was 0.911, and the sensitivity and specificity were 94.7% and 68.4%, respectively, which had higher accuracy than the single-factor model. Conclusion: The multivariate regression model of multimodal ultrasound imaging technology can evaluate the efficacy of neoadjuvant chemotherapy and improve the diagnostic coincidence rate and efficacy.